EGLT Egalet Corporation

4.77
+0  (3%)
Previous Close 4.62
Open 4.71
Price To book 21.39
Market Cap 117.56M
Shares 24,645,000
Volume 489,902
Short Ratio 17.33
Av. Daily Volume 682,340

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

sNDA filed December 1, 2016.
OXAYDO
Acute and chronic moderate to severe pain
Phase 3 to be completed 4Q 2017. NDA planned for 2018.
Egalet-002
Moderate to severe chronic pain
Approved January 9, 2017.
Egalet-001 (ARYMO ER)
Abuse-Deterrent Morphine

Latest News

  1. EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Egalet Corporation - EGLT
  2. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed a Complaint to Recover Losses Suffered by Investors in Egalet Corporation
  3. Blog Coverage Egalet Receives New US and International Patents for Guardian(TM) Technology
  4. Egalet Gets 4 New Patents for Guardian Technology
  5. 6:03 am Egalet announces the issuance of new U.S. and international patents for its proprietary Guardian Technology
  6. Egalet Announces Issuance of New U.S. and International Patents for Guardian™ Technology
  7. INVESTOR NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Egalet Corporation and Encourages Investors with Losses to Contact the Firm
  8. EGLT INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Egalet Corporation and a Lead Plaintiff Deadline of March 28, 2017
  9. Pain Therapeutics’ Remoxy ER Secures FDA Regulatory Guidance (PTIE,EGLT)
  10. Nektar Pharma Opioid Drug Shows Promise In Phase 3
  11. Egalet Corp. :EGLT-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  12. DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Egalet Corporation (EGLT) and Lead Plaintiff Deadline - March 28, 2017
  13. SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Egalet Corporation and Encourages Investors with Losses to Contact the Firm
  14. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Egalet Corporation of Class Action Lawsuit and Upcoming Deadline - EGLT
  15. EGALET CORP Financials
  16. INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed a Complaint to Recover Losses Suffered by Investors in Egalet Corporation
  17. Egalet Corp. :EGLT-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017
  18. SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Egalet Corporation and Encourages Investors with Losses to Contact the Firm
  19. How Endo's FDA Committee Vote Affects Egalet
  20. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Egalet Corporation (EGLT) and Lead Plaintiff Deadline - March 28, 2017